Zacks Investment Research Lowers Ra Pharmaceuticals (RARX) to Sell

Share on StockTwits

Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

RARX has been the topic of several other reports. BidaskClub lowered Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 12th. ValuEngine raised Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, November 16th. Jefferies Financial Group boosted their price target on Ra Pharmaceuticals to $40.00 and gave the stock a “positive” rating in a research report on Monday, December 10th. Finally, BMO Capital Markets set a $21.00 price target on Ra Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $29.00.

Ra Pharmaceuticals stock traded down $0.86 during midday trading on Tuesday, hitting $20.75. 9,648 shares of the company were exchanged, compared to its average volume of 739,938. The firm has a market capitalization of $691.70 million, a PE ratio of -8.75 and a beta of 0.82. Ra Pharmaceuticals has a fifty-two week low of $4.78 and a fifty-two week high of $23.90.

Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.02). On average, sell-side analysts anticipate that Ra Pharmaceuticals will post -2.11 earnings per share for the current year.

In other Ra Pharmaceuticals news, Director Ra Capital Healthcare Fund Lp bought 1,006,452 shares of the business’s stock in a transaction on Wednesday, December 12th. The shares were bought at an average cost of $15.50 per share, with a total value of $15,600,006.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Enterprise Associates 13 L. New bought 645,161 shares of the business’s stock in a transaction on Friday, December 14th. The stock was acquired at an average cost of $15.50 per share, for a total transaction of $9,999,995.50. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 2,658,065 shares of company stock worth $41,200,008. 11.40% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in RARX. BlackRock Inc. raised its position in shares of Ra Pharmaceuticals by 33.3% during the 3rd quarter. BlackRock Inc. now owns 2,049,933 shares of the company’s stock valued at $37,084,000 after acquiring an additional 512,602 shares in the last quarter. First Manhattan Co. raised its position in shares of Ra Pharmaceuticals by 38.1% during the 3rd quarter. First Manhattan Co. now owns 1,073,906 shares of the company’s stock valued at $19,426,000 after acquiring an additional 296,419 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of Ra Pharmaceuticals by 190.0% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 435,000 shares of the company’s stock valued at $7,869,000 after acquiring an additional 285,000 shares in the last quarter. TIAA CREF Investment Management LLC raised its position in shares of Ra Pharmaceuticals by 289.7% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 280,761 shares of the company’s stock valued at $5,079,000 after acquiring an additional 208,720 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Ra Pharmaceuticals by 83.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 394,179 shares of the company’s stock valued at $7,131,000 after acquiring an additional 179,600 shares in the last quarter. 74.74% of the stock is currently owned by institutional investors.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Debt-To-Equity Ratio

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.